{"filing":{"accession_number":"0001193125-26-282873","cik":"0001680581","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"d159102d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526282873/d159102d8k.htm"},"events":[{"id":13949,"run_id":12402,"accession_number":"0001193125-26-282873","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11239,"accession_number":"0001193125-26-282873","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:33:47.150624+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11239,"accession_number":"0001193125-26-282873","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of Fulcrum's 2026 annual stockholder meeting held on June 24, 2026, including election of three Class I directors (Sonja Banks, Alan Ezekowitz, Colin Hill), advisory approval of named executive officer compensation, and ratification of Ernst \u0026 Young LLP as independent auditor. The filing directly reports voting outcomes on these material governance matters, which is the core purpose of Item 5.07 shareholder vote results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:33:47.150624+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-25"}]}